CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin

Overview of attention for article published in Frontiers in Cell and Developmental Biology, July 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 10,192 followers.

The authors of "CD30-Positive Extracellular Vesicles Enable the Ta…" (https://t.co/DVCKpKz50G) included RRIDs in their paper! Thank you for making your #methodsmatter. #reproducibility

08 Sep 2021

Reply Repost Favourite

New article: CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin https://t.co/fBqTCKAxzY #DLBCL #lymsm #hematology https://t.co/hv0R5vSRZV

16 Aug 2021

Reply Repost Favourite

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin #lymphoma #lymsm https://t.co/ezn9aw0a9e

16 Aug 2021

Reply Repost Favourite

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin #lymphoma #lymsm https://t.co/EKOYuamSH3

16 Aug 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.